<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056299</url>
  </required_header>
  <id_info>
    <org_study_id>AIME01</org_study_id>
    <nct_id>NCT04056299</nct_id>
  </id_info>
  <brief_title>Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy</brief_title>
  <official_title>Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aimmune Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aimmune Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of AR201 in a characterized oral desensitization
      immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, randomized, double-blind, placebo-controlled study of the efficacy and
      safety of AR201 in a CODIT regimen in hen egg-allergic subjects aged 4 to 26 years,
      inclusive. The study will be conducted at approximately 30 sites in the United States.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of AR201 in a CODIT regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive, assessed by single highest tolerated dose of at least 1000 mg dried egg white protein in a DBPCFC</measure>
    <time_frame>9-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AR201</measure>
    <time_frame>9-12 months</time_frame>
    <description>2. Efficacy of AR201 assessed by single highest tolerated dose of dried egg white protein in a DBPCFC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Hen Egg Allergy</condition>
  <arm_group>
    <arm_group_label>AR201 powder (Hen Egg Allergen formulation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to active arm of AIME01 and will be administered IP (AR201) in escalating doses for approximately 6 months, followed by a maintenance dose for approximately 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to placebo arm of AIME01 and will be administered escalating doses of IP (placebo) for approximately 6 months, followed by a maintenance dose for approximately 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AR201 Powder</intervention_name>
    <description>AR201 powder provided in capsules (Hen Egg allergen formulation)</description>
    <arm_group_label>AR201 powder (Hen Egg Allergen formulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo powder</intervention_name>
    <description>Placebo powder provided in capsules</description>
    <arm_group_label>Placebo powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age 4 to 26 years, inclusive

          -  Written informed consent from subjects, as appropriate per local requirements, and
             parent/guardian

          -  Written assent from subjects who are minors, as appropriate per local requirements

          -  History of physician-diagnosed hen egg allergy

          -  Elevated egg specific IgE and/or mean wheal diameter on SPT to egg

          -  Experience dose-limiting symptoms at or before the 300 mg challenge dose of dried egg
             white protein on Screening DBPCFC

          -  Use of effective birth control by sexually active female subjects of childbearing
             potential

        Key Exclusion Criteria:

          -  History of severe or life-threatening anaphylaxis within 60 days before screening

          -  History of hen egg allergy such as food protein-induced enterocolitis syndrome (FPIES)

          -  History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal
             disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD),
             symptoms of dysphagia or recurrent gastrointestinal symptoms of unknown etiology

          -  History of a mast cell disorder including systemic mastocytosis, urticaria pigmentosa,
             chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g.,
             cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema

          -  History of chronic disease (except asthma, atopic dermatitis, or allergic rhinitis)
             which may require a change in immunosuppressive medication regimen or chronic
             corticosteroid use

          -  History of cardiovascular disease, including uncontrolled or inadequately controlled
             hypertension

          -  Developing dose-limiting symptoms to placebo challenge during the Screening DBPCFC

          -  Having the same place of residence as another subject in the study

          -  Any other condition that, in the opinion of the Investigator, precludes participation
             for reasons of safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Ashley</last_name>
    <role>Study Director</role>
    <affiliation>Aimmune Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research of Arizona, a division of Allergy, Asthma and Immunology Associates, Ltd.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Associates</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Medical Group and Research Center, A.P.C</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Santa Clara Valley Research Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates, PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Center for Advanced Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy &amp; Asthma Clinic, PA</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060-8950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Allergy LLC, dba Idaho Research</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze, &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Clinical Research, Inc.</name>
      <address>
        <city>White Marsh</city>
        <state>Maryland</state>
        <zip>21162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Allergy Specialty Clinic and Food Allergy Clinic</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute Inc</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center, LLC</name>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Clinical Research dba Columbia Asthma and Allergy</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy and Asthma Research, LLC.</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Allergy &amp; Asthma Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aimmune.com/medical-information-request-form/</url>
    <description>Click to request more information about this study</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CODIT™ (characterized oral desensitization immunotherapy™)</keyword>
  <keyword>Hen Egg Allergic Children</keyword>
  <keyword>Desensitization</keyword>
  <keyword>AR201</keyword>
  <keyword>Allergy</keyword>
  <keyword>Hen Egg Allergy</keyword>
  <keyword>Characterized Hen Egg Allergen</keyword>
  <keyword>Oral Immunotherapy</keyword>
  <keyword>CHEA (Characterized Hen Egg Allergen)</keyword>
  <keyword>Food Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Egg Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

